Clinical Trial Update: Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating Soliqua 100/33 (insulin glargine + lixisenatide) on time-in-range as measured by continuous glucose monitoring in insulin-naive adult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SOLIQUA 100/33 (INSULIN GLARGINE AND LIXISENATIDE)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2024-05-24